MX2009012922A - Vacunacion intradermica de un peptido del virus del papiloma humano. - Google Patents

Vacunacion intradermica de un peptido del virus del papiloma humano.

Info

Publication number
MX2009012922A
MX2009012922A MX2009012922A MX2009012922A MX2009012922A MX 2009012922 A MX2009012922 A MX 2009012922A MX 2009012922 A MX2009012922 A MX 2009012922A MX 2009012922 A MX2009012922 A MX 2009012922A MX 2009012922 A MX2009012922 A MX 2009012922A
Authority
MX
Mexico
Prior art keywords
intradermal
peptide vaccination
hpv peptide
hpv
medicament
Prior art date
Application number
MX2009012922A
Other languages
English (en)
Spanish (es)
Inventor
Sjoerd Henricus Van Der Burg
Gemma G Kenter
Cornelis Johannes Maria Melief
Original Assignee
Academisch Ziekenhuis Leiden H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden H filed Critical Academisch Ziekenhuis Leiden H
Publication of MX2009012922A publication Critical patent/MX2009012922A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MX2009012922A 2007-05-31 2008-05-27 Vacunacion intradermica de un peptido del virus del papiloma humano. MX2009012922A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94107007P 2007-05-31 2007-05-31
EP07109287 2007-05-31
PCT/NL2008/050315 WO2009002159A2 (en) 2007-05-31 2008-05-27 Intradermal hpv peptide vaccination

Publications (1)

Publication Number Publication Date
MX2009012922A true MX2009012922A (es) 2010-07-05

Family

ID=38477016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012922A MX2009012922A (es) 2007-05-31 2008-05-27 Vacunacion intradermica de un peptido del virus del papiloma humano.

Country Status (10)

Country Link
US (2) US9562075B2 (enExample)
EP (1) EP2155240B1 (enExample)
JP (2) JP2010530362A (enExample)
CN (1) CN101795705A (enExample)
AU (1) AU2008269721B2 (enExample)
BR (1) BRPI0812311A8 (enExample)
CA (1) CA2688589A1 (enExample)
ES (1) ES2482192T3 (enExample)
MX (1) MX2009012922A (enExample)
WO (1) WO2009002159A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468763B1 (en) * 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
EP2344191A4 (en) * 2008-09-02 2013-02-13 Antigen Express Inc HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE
EP2646459B1 (en) 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
CN108289913A (zh) 2015-10-30 2018-07-17 儿童国家医疗中心 从未致敏t细胞群体产生hpv抗原特异性t细胞
WO2017083963A1 (en) 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
SG11201811442UA (en) * 2016-06-20 2019-01-30 Isa Pharmaceuticals B V Formulation of a peptide vaccine
US11524063B2 (en) * 2017-11-15 2022-12-13 Arizona Board Of Regents On Behalf Of Arizona State University Materials and methods relating to immunogenic epitopes from human papillomavirus
AU2019234549B2 (en) 2018-03-12 2026-02-12 Sqz Biotechnologies Company Methods for treating HPV-associated diseases
US20240374654A2 (en) * 2018-03-12 2024-11-14 Stemcell Technologies Canada Inc. Intracellular delivery of biomolecules to modify immune response
MA52363A (fr) * 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
EP4271407A1 (en) * 2020-12-29 2023-11-08 SQZ Biotechnologies Company Formulations of activating antigen carriers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US5932412A (en) 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
DE9106105U1 (de) * 1991-05-17 1991-11-07 Behringwerke Ag, 3550 Marburg Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
AU721927B2 (en) 1995-12-22 2000-07-20 Immunomedics Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
ATE304375T1 (de) 1998-05-23 2005-09-15 Univ Leiden Medical Ct Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6641994B2 (en) * 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
EP1417353A4 (en) * 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH HPV ASSOCIATED PENCILS AND CANNULAR WELLS, INCLUDING CIN
US6884605B2 (en) * 2001-08-09 2005-04-26 Board Of Trustees Of The University Of Arkansas Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
WO2005063286A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
CA2609927A1 (en) * 2005-04-27 2006-11-02 Leiden University Medical Center Methods and means for the treatment of hpv induced intraepithelial neoplasias
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Also Published As

Publication number Publication date
AU2008269721B2 (en) 2013-01-10
JP2010530362A (ja) 2010-09-09
WO2009002159A3 (en) 2009-02-12
US20100196353A1 (en) 2010-08-05
BRPI0812311A2 (pt) 2014-10-29
US9562075B2 (en) 2017-02-07
ES2482192T3 (es) 2014-08-01
EP2155240A2 (en) 2010-02-24
JP2014185179A (ja) 2014-10-02
CA2688589A1 (en) 2008-12-31
EP2155240B1 (en) 2014-04-30
CN101795705A (zh) 2010-08-04
BRPI0812311A8 (pt) 2019-02-05
US20170143818A1 (en) 2017-05-25
JP5888823B2 (ja) 2016-03-22
AU2008269721A1 (en) 2008-12-31
WO2009002159A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
MX2009012922A (es) Vacunacion intradermica de un peptido del virus del papiloma humano.
WO2008087190A3 (en) Use of peptides in combination with surgical intervention for the treatment of obesity
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
TW200744642A (en) Novel peptides for use in the treatment of obesity
WO2008087186A3 (en) Peptides for use in the treatment of obesity
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MY162741A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin D1
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2014003312A (es) Analogos de glucagon novedosos.
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MX347471B (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
SI2148670T1 (sl) Titracija tapentadola
WO2008087188A3 (en) Peptides for use in the treatment of obesity
PL2081910T3 (pl) Nowe związki
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
NZ594347A (en) Antibodies against human tweak and uses thereof
WO2008087189A3 (en) Peptides for use in the treatment of obesity
MX2011008261A (es) FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1.
WO2008043788A3 (en) Novel compounds
TN2012000217A1 (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
WO2009120022A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
MX2012000541A (es) Peptidos, polipeptidos y secuencias de acidos nucleicos terapeuticos.
EA201000738A1 (ru) Медицинское применение 3-(2,2,2-триметилгидразиниум)пропионат гидрофумарата и дигидрофосфата

Legal Events

Date Code Title Description
FG Grant or registration